We are live on
!
Find out more
BM
Bridger Management Portfolio holdings
AUM
$128M
1-Year Est. Return
9.54%
This Fund
S&P 500
This Quarter
Est. Return
+1.33%
1 Year Est. Return
+9.54%
3 Year Est. Return
+98.31%
5 Year Est. Return
+125.76%
10 Year Est. Return
+911.97%
AUM
$331M
AUM Growth
-$113M
(-25%)
Cap. Flow
-$103M
Cap. Flow
% of AUM
-31.27%
Top 10 Holdings %
Top 10 Hldgs %
56.38%
Holding
49
New
6
Increased
7
Reduced
16
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Uber
UBER
|
+$6.98M |
| 2 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$5.79M |
| 3 |
MDU Resources
MDU
|
+$5.1M |
| 4 |
RCM
R1 RCM Inc. Common Stock
RCM
|
+$4.3M |
| 5 |
STAAR Surgical
STAA
|
+$3.98M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Centene
CNC
|
+$25.9M |
| 2 |
Clarivate
CLVT
|
+$22.7M |
| 3 |
AstraZeneca
AZN
|
+$14M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$9.58M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$9.56M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 39.32% |
| 2 | Technology | 21.77% |
| 3 | Financials | 11.08% |
| 4 | Communication Services | 6.26% |
| 5 | Consumer Staples | 5.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
BellRing Brands
BRBR
$1.48B
| $3.86M | 1.17% |
187,122
| – | – |
|
|
BPMC
27
DELISTED
Blueprint Medicines
BPMC
| $3.51M | 1.06% |
+53,300
| New | +$3.42M |
|
|
28
STAAR Surgical
STAA
$1.2B
| $3.28M | 0.99% |
+46,536
| New | +$3.98M |
|
29
RxSight
RXST
$247M
| $2.66M | 0.81% |
221,732
-109,700
| -33% | -$1.51M |
|
|
30
Centene
CNC
$30.6B
| $2.2M | 0.67% |
28,263
-290,037
| -91% | -$25.9M |
|
31
Quanterix
QTRX
$160M
| $2.19M | 0.66% |
198,600
+53,916
| +37% | +$686K |
|
|
ABCM
32
DELISTED
Abcam PLC
ABCM
| $2.13M | 0.65% |
142,350
| – | – |
|
33
Xenon Pharmaceuticals
XENE
$6.07B
| $1.63M | 0.49% |
45,235
-32,165
| -42% | -$1.16M |
|
34
Privia Health
PRVA
$2.97B
| $1.63M | 0.49% |
47,703
+3,303
| +7% | +$122K |
|
35
Surrozen
SRZN
$247M
| $1.41M | 0.43% |
46,667
| – | – |
|
36
LivaNova
LIVN
$4.4B
| $1.36M | 0.41% |
26,790
-29,100
| -52% | -$1.73M |
|
37
Melco Resorts & Entertainment
MLCO
$2.25B
| $1.33M | 0.4% |
+200,000
| New | +$1.1M |
|
38
Toast
TOST
$18.5B
| $881K | 0.27% |
+52,692
| New | +$914K |
|
39
Nautilus Biotechnolgy
NAUT
$121M
| $877K | 0.27% |
413,700
+124,700
| +43% | +$314K |
|
|
DMTK
40
DELISTED
DermTech, Inc. Common Stock
DMTK
| $826K | 0.25% |
208,600
-142,200
| -41% | -$874K |
|
41
AdvisorShares Pure US Cannabis ETF
MSOS
$862M
| $499K | 0.15% |
55,958
-158,142
| -74% | -$1.83M |
|
|
NEXI
42
DELISTED
NexImmune, Inc. Common Stock
NEXI
| $222K | 0.07% |
16,000
| – | – |
|
|
43
Surrozen Inc Warrant
SRZNW
$69.7K
| $129K | 0.04% |
699,999
+233,333
| +50% | +$64.8K |
|
|
WRAC.WS
44
DELISTED
Williams Rowland Acquisition Corp. Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50
WRAC.WS
| $28K | 0.01% |
475,000
| – | – |
|
|
45
Clarivate
CLVT
$1.23B
| – | – |
-1,641,319
| Closed | -$22.7M |
|
46
Insulet
PODD
$11.4B
| – | – |
-41,000
| Closed | -$8.94M |
|
47
Bio-Techne
TECH
$11.2B
| – | – |
-5,776
| Closed | -$501K |
|
48
Viridian Therapeutics
VRDN
$2.09B
| – | – |
-66,300
| Closed | -$767K |
|
|
IMGN
49
DELISTED
Immunogen Inc
IMGN
| – | – |
-278,000
| Closed | -$1.25M |
|
Similar funds
SHFC
IUC
PC
SIM
PIA
S
CF
BC
Bridger Management's Q3 2022 Portfolio in Review
As of Q3 2022, Bridger Management held 49 positions worth $331M, down 25% from $444M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Bridger Management withdrew a net $103M in Q3 2022, closing 5 positions and reducing 16 holdings. Its most notable exit was Clarivate, an estimated $22.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 46% a quarter earlier, followed by Technology and Financials.
Against the trend, Bridger Management opened a new position in Karuna Therapeutics, Inc. Common Stock worth $6.43M.
- Bridger Management's largest Q3 2022 buy was Karuna Therapeutics, Inc. Common Stock: 28,600 shares worth $6.43M.
- Bridger Management added most to Uber in Q3 2022, an estimated $6.98M increase.
- Bridger Management's biggest Q3 2022 reduction was Centene, cutting an estimated $25.9M.
- Bridger Management fully exited Clarivate in Q3 2022, selling an estimated $22.7M.
- Bridger Management's ten largest holdings make up 56% of its $331M portfolio in Q3 2022.
- Bridger Management opened 6 new positions and closed 5 in Q3 2022.
- Bridger Management's portfolio value fell 25% quarter-over-quarter to $331M.
Based on Bridger Management's 13F filing for Q3 2022, filed 14 Nov 2022.